{"id":576,"date":"2015-05-05T12:19:00","date_gmt":"2015-05-05T12:19:00","guid":{"rendered":"http:\/\/bxta-staging.website\/?p=576"},"modified":"2021-12-17T10:13:27","modified_gmt":"2021-12-17T10:13:27","slug":"ascende-rt-study","status":"publish","type":"post","link":"https:\/\/bxta.com\/es\/ascende-rt-study\/","title":{"rendered":"Estudio ASCENDE-RT: pacientes con riesgo intermedio y alto de c\u00e1ncer de pr\u00f3stata tienen el doble de tasa de supervivencia con las semillas de braquiterapia"},"content":{"rendered":"
\n

Estudio ASCENDE-RT: pacientes con riesgo intermedio y alto de c\u00e1ncer de pr\u00f3stata tienen el doble de tasa de supervivencia con las semillas de braquiterapia<\/strong><\/h3><\/div><\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n

BXTAccelyon Limited, la empresa de braquiterapia con base en el Reino Unido que suministra semillas, packs de agujas cargadas y accesorios relacionados, as\u00ed como equipamiento a hospitales y cl\u00ednicas de todo el mundo ha sido requerido para revisar la disponibilidad de braquiterapia por semillas de pacientes con riesgo intermedio y elevado de c\u00e1ncer de pr\u00f3stata. Seguimos con la presentaci\u00f3n de datos del ensayo de ASCENDE RT en la reciente Conferencia ESTRO de Barcelona sobre el aumento de la dosis de radioterapia para dichos pacientes.<\/p>\n\n\n\n

La Braquiterapia de dosis baja (LDR) es una forma de terapia por radiaci\u00f3n que se basa en colocar diminutas \u00absemillas\u00bb radioactivas directamente en el interior de la pr\u00f3stata. El ensayo ASCENDE-RT, realizado en Canad\u00e1, es un ensayo aleatorio que compara la utilizaci\u00f3n de radioterapia con radiaci\u00f3n externa escalada en dosis (DE-EBRT) frente a la braquiterapia de baja dosis (LDR-B) en hombres con riesgo intermedio o alto de c\u00e1ncer de pr\u00f3stata. Resumiendo, el ensayo demostr\u00f3 un descenso del 50% de la reincidencia bioqu\u00edmica al utilizar la LDR-B junto con un tratamiento hormonal y radioterapia completa de pelvis frente a la DE-EBRT con los mismos tratamientos en pacientes asignados aleatoriamente en ambas formas de tratamiento.<\/p>\n\n\n\n

Al a\u00f1o se diagnostican alrededor de 45.000 1,2<\/sup> nuevos casos 1,2 en el Reino Unido e Irlanda, y dos de cada tres de esos pacientes est\u00e1n en un estadio temprano de la enfermedad, lo cual hace que sean adecuados para el tratamiento con braquiterapia LDR. En la actualidad, m\u00e1s de 1500 pacientes reciben tratamiento mediante braquiterapia con semillas al a\u00f1o en centros del Reino Unido e Irlanda3. Al a\u00f1o se diagnostican alrededor de 23.000 4,5<\/sup> nuevos casos 4,5 en Australia y Nueva Zelanda, y m\u00e1s de dos de cada tres de esos pacientes est\u00e1n en un estadio temprano de la enfermedad, lo cual hace que sean adecuados para el tratamiento con braquiterapia LDR.<\/p>\n\n\n\n

Saheed Rashid, Director General de BXTAccelyon, a\u00f1ade: \u00abEste tipo de informaci\u00f3n puede ayudar a los sanitarios cl\u00ednicos y asesores de los servicios de salud a determinar cu\u00e1l es el mejor tratamiento para los pacientes de c\u00e1ncer de pr\u00f3stata. El estudio es extremadamente valioso para resaltar la necesidad de un cambio en la pr\u00e1ctica cl\u00ednica de cara a que los hombres con este tipo de enfermedad accedan a un tratamiento que les de el cincuenta por ciento m\u00e1s de oportunidades de estar libres de la enfermedad a largo plazo. Junto a la adecuaci\u00f3n y los beneficios en t\u00e9rminos de ahorro de costes de la braquiterapia de semillas como tratamiento opcional y la \u00abliberaci\u00f3n\u00bb de un tiempo valioso en los dispositivos que utilizamos para dar la radioterapia, este estudio, adem\u00e1s de ser realmente importante para los pacientes de c\u00e1ncer de pr\u00f3stata, tambi\u00e9n lo es para tratar a otros pacientes con otros tipos de c\u00e1ncer\u00bb.<\/p>\n\n\n\n

\n
<\/div>
Ascende-RT Data Sheet (EN)<\/a><\/a><\/div><\/div><\/div>\n\n\n\n
<\/div>
Ascende-RT Data Sheet (NL)<\/a><\/a><\/div><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

Para m\u00e1s informaci\u00f3n, p\u00f3ngase en contacto con:<\/p>\n\n\n\n

Saheed Rashid (Director General)
E: saheed.rashid@bxta.com
T: +44(0)7979-327526
W: www.bxta.com<\/p>\n\n\n\n

Referencias:
1. Centro de Estad\u00edstica Nacional: Cancer registry statistics \u2013 England, Scotland, Wales & Northern Ireland UK Ref 1-6
2. 6. National Cancer Registry Ireland: Cancer Trends
3. www.prostatebrachytherapyinfo.net UK and Ireland Brachytherapy Centres and Procedure numbers.
4. Australian Insititute of Health and Welfare Cancer in Australia 2012 and Cancer Incidence Projections
5. Inquiry into early detection and treatment of prostate cancer Report to Health Committee NZ House of Representatives July 2011, Cancer Statistics,www.health.govt.nz\/nz-health-statistics\/publications-data-sets-and-stats\/cancer-data-and-stats<\/p>\n\n\n\n

Notas:
BXTAccelyon Limited is a UK company with Registered Office at The Coach House, Grenville Court, Britwell Road, Burnham SL1 8DF UK.<\/p>\n<\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-576","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"\nASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bxta.com\/es\/ascende-rt-study\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bxta.com\/es\/ascende-rt-study\/\" \/>\n<meta property=\"og:site_name\" content=\"BXTA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bxtainternational\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-05T12:19:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-17T10:13:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg\" \/>\n<meta name=\"author\" content=\"Marketing BXTA\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BXTA_\" \/>\n<meta name=\"twitter:site\" content=\"@BXTA_\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marketing BXTA\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\"},\"author\":{\"name\":\"Marketing BXTA\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/person\\\/be7f4368cd4f7e11918870d00223473a\"},\"headline\":\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds\",\"datePublished\":\"2015-05-05T12:19:00+00:00\",\"dateModified\":\"2021-12-17T10:13:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\"},\"wordCount\":528,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\",\"url\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\",\"name\":\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\",\"datePublished\":\"2015-05-05T12:19:00+00:00\",\"dateModified\":\"2021-12-17T10:13:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\",\"contentUrl\":\"https:\\\/\\\/bxta-staging.website\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/ezgif.com-webp-to-jpg-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bxta.com\\\/ascende-rt-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/bxta.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#website\",\"url\":\"https:\\\/\\\/bxta.com\\\/uk\\\/\",\"name\":\"BXTA\",\"description\":\"Let\u2019s tackle Prostate Cancer together | BXTA\",\"publisher\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bxta.com\\\/uk\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\",\"name\":\"BXTA\",\"url\":\"https:\\\/\\\/bxta.com\\\/uk\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/bxta-staging.s3.eu-west-2.amazonaws.com\\\/app\\\/uploads\\\/2021\\\/09\\\/07212056\\\/BXTA-Logo.png\",\"contentUrl\":\"https:\\\/\\\/bxta-staging.s3.eu-west-2.amazonaws.com\\\/app\\\/uploads\\\/2021\\\/09\\\/07212056\\\/BXTA-Logo.png\",\"width\":600,\"height\":373,\"caption\":\"BXTA\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bxtainternational\\\/\",\"https:\\\/\\\/x.com\\\/BXTA_\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/bxtaccelyon\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCkTU9L10CS5c1eWtGiMZ7gw\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/person\\\/be7f4368cd4f7e11918870d00223473a\",\"name\":\"Marketing BXTA\",\"url\":\"https:\\\/\\\/bxta.com\\\/es\\\/author\\\/marketingbxta\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bxta.com\/es\/ascende-rt-study\/","og_locale":"es_ES","og_type":"article","og_title":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA","og_url":"https:\/\/bxta.com\/es\/ascende-rt-study\/","og_site_name":"BXTA","article_publisher":"https:\/\/www.facebook.com\/bxtainternational\/","article_published_time":"2015-05-05T12:19:00+00:00","article_modified_time":"2021-12-17T10:13:27+00:00","og_image":[{"url":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","type":"","width":"","height":""}],"author":"Marketing BXTA","twitter_card":"summary_large_image","twitter_creator":"@BXTA_","twitter_site":"@BXTA_","twitter_misc":{"Escrito por":"Marketing BXTA","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bxta.com\/ascende-rt-study\/#article","isPartOf":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/"},"author":{"name":"Marketing BXTA","@id":"https:\/\/bxta.com\/uk\/#\/schema\/person\/be7f4368cd4f7e11918870d00223473a"},"headline":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds","datePublished":"2015-05-05T12:19:00+00:00","dateModified":"2021-12-17T10:13:27+00:00","mainEntityOfPage":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/"},"wordCount":528,"commentCount":0,"publisher":{"@id":"https:\/\/bxta.com\/uk\/#organization"},"image":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage"},"thumbnailUrl":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","articleSection":["News"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/bxta.com\/ascende-rt-study\/","url":"https:\/\/bxta.com\/ascende-rt-study\/","name":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds - BXTA","isPartOf":{"@id":"https:\/\/bxta.com\/uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage"},"image":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage"},"thumbnailUrl":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","datePublished":"2015-05-05T12:19:00+00:00","dateModified":"2021-12-17T10:13:27+00:00","breadcrumb":{"@id":"https:\/\/bxta.com\/ascende-rt-study\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bxta.com\/ascende-rt-study\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/bxta.com\/ascende-rt-study\/#primaryimage","url":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg","contentUrl":"https:\/\/bxta-staging.website\/wp-content\/uploads\/2020\/06\/ezgif.com-webp-to-jpg-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/bxta.com\/ascende-rt-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bxta.com\/"},{"@type":"ListItem","position":2,"name":"ASCENDE RT study: intermediate and high risk prostate cancer patients have double the survival chance with brachytherapy seeds"}]},{"@type":"WebSite","@id":"https:\/\/bxta.com\/uk\/#website","url":"https:\/\/bxta.com\/uk\/","name":"BXTA","description":"Hagamos frente juntos al c\u00e1ncer de pr\u00f3stata | BXTA","publisher":{"@id":"https:\/\/bxta.com\/uk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bxta.com\/uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/bxta.com\/uk\/#organization","name":"BXTA","url":"https:\/\/bxta.com\/uk\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/bxta.com\/uk\/#\/schema\/logo\/image\/","url":"https:\/\/bxta-staging.s3.eu-west-2.amazonaws.com\/app\/uploads\/2021\/09\/07212056\/BXTA-Logo.png","contentUrl":"https:\/\/bxta-staging.s3.eu-west-2.amazonaws.com\/app\/uploads\/2021\/09\/07212056\/BXTA-Logo.png","width":600,"height":373,"caption":"BXTA"},"image":{"@id":"https:\/\/bxta.com\/uk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bxtainternational\/","https:\/\/x.com\/BXTA_","https:\/\/www.linkedin.com\/company\/bxtaccelyon","https:\/\/www.youtube.com\/channel\/UCkTU9L10CS5c1eWtGiMZ7gw"]},{"@type":"Person","@id":"https:\/\/bxta.com\/uk\/#\/schema\/person\/be7f4368cd4f7e11918870d00223473a","name":"Marketing BXTA","url":"https:\/\/bxta.com\/es\/author\/marketingbxta\/"}]}},"_links":{"self":[{"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/posts\/576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/comments?post=576"}],"version-history":[{"count":7,"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/posts\/576\/revisions"}],"predecessor-version":[{"id":3215,"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/posts\/576\/revisions\/3215"}],"wp:attachment":[{"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/media?parent=576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/categories?post=576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bxta.com\/es\/wp-json\/wp\/v2\/tags?post=576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}